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Introduction
Regulatory authorities around the globe face challenges
of keeping pace with innovations in the food and agricultural
sectors. Without any doubt the most challenging innovations
– and on those this contribution focuses – concern products
not formerly known in the jurisdiction at issue.
In the 1950s and 1960s chemistry was a frontier science
providing agriculture with herbicides and pesticides and food
processing with synthetic additives. Later, gene technology
developed crops and foods that had hitherto been unknown.
Currently, innovations in food production are expected from
nanotechnology and animal cloning.
New products in this sense, however, do not only come
from laboratories. New foods may also originate from
discoveries in other geographical areas. Products that are
new to a region but have a history elsewhere are often
referred to as ‘exotic’.
This wide variety of new foods presents authorities with
challenges. What is their responsibility in this respect? How
do they have to react? Can best practices be derived from
international experience?
This article addresses these questions from the angle of
legal scholarship. We apply a comparative approach gaining
insights from different jurisdictions around the world. Empirics
will be derived from legal-economic studies, indicating
concerns experienced in practice. From this combined
perspective, possible regulatory strategies will be proposed.
Core issue in the regulatory approaches to innovations in
food and agriculture are prior authorization schemes
requiring a proof of safety before a product belonging to a
certain category of products can be placed on the market.
Similar approaches are found in the areas of medicines,
veterinary drugs and pesticides. The analysis in this
contribution, however, is limited to foods and agricultural
products intended for human consumption.
This article addresses the following questions. How have
prior authorization schemes developed? What are the critical
issues? To which concerns have authorization schemes given
rise? Which best practices have emerged to deal with these
concerns? What can regulators do to face the challenge from
product innovation in food and agriculture?
The article is structured as follows: Section II introduces
the international meta-framework with which national
regulatory systems should comply; Section III discusses
schemes that have developed in the EU and US; Section IV
describes an example of pre-market approval schemes – the
EU procedure for novel foods – in more detail; Section V
lays out some concerns regarding pre-market authorization




If national regulatory systems (including regional
systems) want to fit into the international community, they
need to comply with requirements of international law. In the
international arena a framework of requirements has
developed that applies (not to the behaviour of people and
businesses, but) to the national legal systems, and can thus be
considered a meta-framework (Meulen van der 2010).
At the global level different players contribute to this
meta-framework for food and agriculture. The United
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Nations (UN) lays emphasis on human rights. The Food and
Agricultural Organization (FAO) and the World Health
Organization (WHO) have the lead in the core elements of
standard setting: risk assessment and risk management. The
World Trade Organization (WTO) plays a major role in
application of food standards in trade and dispute resolution.
The WHO operates risk communication structures, seminal
in incident management. For our analysis, the food standard
developed by FAO/WHO and trade agreements concluded
within the WTO are relevant.
International standard setting
Risk assessment
Risk assessment for international standard setting is
undertaken in three main joint FAO and WHO panels: Joint
FAO/WHO Expert Committee on Food Additives (JECFA),
Joint FAO/WHO Meetings on Pesticide Residues (JMPR)
and Joint FAO/WHO Meetings on Microbiological Risk
Assessment (JEMRA). They advise on maximum limits for
food additives, pesticide residues, microbes and on other
food safety issues.
Risk management: Codex Alimentarius Commission
In 1963 the FAO and WHO established the Codex
Alimentarius Commission (CAC), consisting of specialized
committees, hosted by member states all over the world.
Some 175 countries participate in their work. Food standards
are established through an elaborate procedure of
international negotiations (FAO/WHO 2006). All standards
together are called ‘Codex Alimentarius’ (Latin for ‘food
code’). Apart from standards, Codex also includes advisory
provisions called codes of practice or guidelines, mainly
addressing food businesses. At present, Codex comprises
more than 200 standards, close to 50 food hygiene and
technological codes of practice, some 60 guidelines, over
1,000 food additives and contaminants evaluations and over
3,200 maximum residue limits for pesticides and veterinary
drugs (FAO/WHO 2002; Knudsen et al. 2008; Masson-
Matthee 2007; FAO/WHO 2006).
Codex standards do not as such have legal effect on
people and businesses. To acquire such effect, they need to be
implemented in national legislation.
Trade and dispute settlement
The WTO endeavours to liberalize international trade. It
is a system based on negotiations. When countries face
barriers to trade and want them lowered, the WTO is a
platform for negotiating the opening of national markets and
removing as many obstacles to trade as possible without
undesirable effects. The core of the WTO system are the
WTO Agreements, providing rules for international trade.
The main agreement concerning trade in goods concluded
within the WTO is the General Agreement on Tariffs and
Trade (GATT). In some circumstances, however, WTO rules
support maintaining trade barriers – to protect higher values.
Article XX(b) of GATT recognizes that exceptions to free
trade can be necessary to protect human, animal or plant life
or health.
The WTOAgreement on the Application of Sanitary and
Phytosanitary Measures (SPS Agreement)1 aims to ensure
that countries only apply measures to protect human and
animal health (sanitary measures) and plant health
(phytosanitary measures) based on the assessment of risk, or
-– in other words – based on science. However, if the
measures are in conformity with international standards, no
scientific proof of necessity is required. These measures are
by definition considered necessary. For food, these
international standards are in the Codex Alimentarius. WTO
members who follow Codex standards need not prove the
necessity of their SPS measures.
WTO agreements bindWTO member states. The Dispute
Settlement Understanding provides a procedure to resolve
conflicts. If a party so requires, the Dispute Settlement Body
forms a panel to deal with the issue. Panel decisions can be
appealed to the Appellate Body. The WTO cannot enforce
decisions taken in this procedure, but it can allow the
winning party to implement economic sanctions if the party
found at fault does not comply. These sanctions are usually




Before the 20th century, new foods and crops were not
seen as a matter of concern for authorities. One of the first
pre-market approval schemes was introduced in 1958 in the
United States. Concerns about the application of chemicals
in food processing led to the introduction of an approval
requirement for food additives (Table 1). Products within the
definition of ‘additive’ need to be authorized or to enjoy
GRAS status. Failing this, foods containing them are
considered adulterated.
This concept of food additive is much wider than the
concept of food additive in the Codex Alimentarius2 (and in
the EU) in that it is not limited to substances with a
technological function. A food additive in this wide sense of
the word that has not been on the US market before 1958 has
to undergo safety assessment, except when it is ‘Generally
Recognized As Safe’ (GRAS). In other words, when within
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the scientific community consensus has been reached on the
safety of a certain product (category), it no longer needs to be
assessed by the authorities.3 Separate authorization
requirements apply to colour additives and dietary
supplements.
European Union
Back in 1958 when the USA introduced its scheme for
food additives, the European Economic Community (now the
European Union) was only just starting its activities. One of
the earliest examples of harmonisation of national laws can
be found in legislation on colorants. The directive concerning
the colouring matters authorized for use in foodstuffs
intended for human consumption set out to harmonise
Member States’ legislation by establishing a single list of
colouring matters the use of which is authorized for
colouring foodstuffs and laying down criteria of purity which
those colouring matters must satisfy.4 As a result, one of the
first positive lists in the EU was created. The list is a part of
the law (in this case an annex to the directive). To include
later a product in the list (or delete it from the list), the law
must be changed by the applicable procedure.
While the details differ greatly, positive lists or similar
market authorization requirements exist in EU food law, as
well as in Member States’ food law. Examples at EU level
include food additives (including sweeteners, colourants,
etc.)5 flavourings,6 extraction solvents,7 infant formulae and
follow-on formulae,8 foodstuffs intended for particular
nutritional uses,9 food supplements,10 genetically modified
(GM) food and feed,11 food contact materials,12 nutrition and
health claims made on foods,13 and novel foods.14
Some Lists are More Positive than others
From the above follows that case-by-case risk
assessments preceding the placing on the market of new
products is a common feature in regulatory responses to
innovations in food and agriculture in many parts of the
world and – to a certain extent – also at the global level of the
Codex Alimentarius. Within the world of positive lists,
however, we find many different flavours. The most
important differences are discussed below.
Object of authorization
Different categories of foods are submitted to premarket
approval. Some products are subject to premarket approval
based on certain processes that have been applied to them.
An example of such a procedure is the regulation on GM
foods in the EU. The pre-market approval responds to
consumers’ concerns to ensure the safety of food products
which have been produced with help of modern
biotechnology. Another category of pre-market approvals
refers to food or food ingredients new to the market and
which will be used for a certain purpose, e.g. food additives
or processing aids. The Regulation on novel foods in the EU
provides an example of a regulatory scheme for foods that
are new because they have no history of safe use prior to a
single cut-off date (15 May 1997).15
Subject of authorization
To whom does the authorization grant rights? Generally
speaking, authorization schemes come in two different
forms. Some schemes are specific in that they address the
applicant (applicant-linked). Others are generic in that they
address the product. In a generic scheme, the product is
3 On a voluntary basis, Food and Drug Administration’s opinion can be sought.
4 OJ 1962, pp. 2645-2654.
5 Reg. 1333/2008 on food additives, OJ 2008, L 354/16.
6 Reg. 1334/2008 on flavourings, OJ 2008, L 354/34.
7 Dir. 2009/32 on extraction solvents, OJ 2009, L 141/3.
8 Dir. 2006/141 on infant formulae and follow-on formulae, OJ 2006, L 401/1.
9 Dir. 2009/39 on foodstuffs intended for particular nutritional uses, OJ 2009, L 124/21.
10 Dir. 2002/46 on food supplements, OJ 2002, L 183/51.
11 Reg. 1829/2003 on genetically modified food and feed, OJ 2003, L 268/1.
12 Reg. 1935/2004 on materials and articles intended to come into contact with food, OJ 2004, L 338/4.
13 Reg. 1924/2006 on nutrition and health claims made on foods, OJ 2007, L 404/3.
14 Reg. 258/97 concerning novel foods and novel food ingredients, OJ 1997, L 43/1.
15 Regulatory framework based on similar criteria exist also in Australia and New Zealand. To some extent, food additives regulation in the US is also based
on a cut-off date.
Table 1. Section 201(s) FFDCA [21 USC 321].
The term “food additive” means any substance the intended use of which
results or may reasonably be expected to result, directly or indirectly, in
its becoming a component or otherwise affecting the characteristics of
any food (including any substance intended for use in producing,
manufacturing, packing, processing, preparing, treating, packaging,
transporting, or holding food; and including any source of radiation
intended for any such use), if such substance is not generally recognized,
among experts qualified by scientific training and experience to evaluate
its safety, as having been adequately shown through scientific procedures
(or, in the case of a substance used in food prior to January 1, 1958,
through either scientific procedures or experience based on common use
in food) to be safe under the conditions of its intended use.
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placed on the (positive) list. All businesses are allowed to
bring the authorized product to the market. In a specific
scheme, the authorization decision addresses the applicant,
authorizing the applicant to bring the product at issue to the
market. All others who would want to bring an identical
product to the market need an authorization as well (usually
through a simplified procedure).
Applicant-linked schemes reward the applicant for the
investment made in the safety assessment and in the
procedure by granting him an exclusive right. The downside
is that repeated procedures are required, even though the
outcome of the risk assessment is already known to the
authorities (the product is safe and allowed on the market).
Generic schemes reward the second to come to the market
who benefits from the investment made by the applicant,
without having made the effort.
Currently, the EU is experimenting with an in-between
form: data protection. If the application is based on
proprietary data, these data can be used only to the benefit of
the applicant for a certain period. Thus, innovative foods
based on considerable product development could be granted
a specific authorization to protect the applicant. Only after
the data protection period has elapsed, the authorization
could become generic. Applicants who would like to enter
the market before that time would have to provide their own
data. Data protection rewards the investment made in
scientific research, not in the approval procedure as such.
Assessment
A decided advantage of a prior authorization procedure
on a case-by-case basis is that all the uncertainties that
surround food and agricultural innovations can be given a
place. In all procedures, be they positive lists or
authorizations for specific foods, applicants have an interest
to actively contribute to solving problems. In the case of
applications for the authorization of a new food additive
(positive list), a full technical dossier must be submitted
showing that a reasonable technological need exists for the
proposed food additive, that it presents no hazard to the
health of consumers and does not mislead them (EC 2001).
Similar requirements are set for businesses sponsoring a
novel food (individual authorization). An application must
scrupulously identify the product and present evidence that a
product is safe to consumers and – if need be – adequately
labelled not to mislead them.16
Finally, it has to be mentioned that most prior
authorization schemes apply only negative criteria, that is to
say they focus on risks and do not take into account benefits.
One of the current debates on risk assessment raises the issue
if benefits can be accepted to outweigh certain risks such as
(potential) allergenic properties (EFSA 2006). In
pharmaceutical law, for example, usually it is accepted that a
beneficial medicine may have certain side-effects. In foods,
side effects are usually not accepted.
GRAS
In the EU system of prior authorization for novel foods
no exception exists to the requirement that all foods that were
not on the market before the cut-off date must be explicitly
approved. There is no possibility to exclude certain
categories from this requirement when it has been
sufficiently established that the category as such does not
pose a relevant risk. If over time science would establish that
a certain new type of process does not give rise to safety
concerns, in theory each next product made with this process
would still have to undergo safety assessment. To put it more
simply, in the EU system there is no way out of novelty. The
American system may hold a solution to this problem in the
concept of ‘GRAS’. A food additive that has not been on the
US market before 1958 has to undergo safety assessment,
except when it is ‘Generally Recognized As Safe’ (GRAS).
This is the case when consensus has been reached within the
scientific community on the safety of a certain product or
category of products. In that case, risk assessment is no
longer required by the authorities.
Concerns
Trade barriers
In literature it has been argued that prior authorization
schemes hamper innovation. Brookes in his analysis of the
economic impact of the novel foods approval procedures on
the EU food sector finds that it is fairly common for the costs
associated with meeting regulatory requirements to be
between € 0.3 million and € 4 million, and that the
considerable additional time taken to authorize novel foods
in the EU adds an extra € 0.3 million to € 0.75 million per
application (Brookes 2007). Further, he concludes that the
rate of return of the costs made on these investments would
be around 25% if the procedure were to take 6 months. If
delayed to 2.5 to 3 years, the rate decreases to 17%-18%, and
if it is extended to five years (60 months), it becomes
negative as the rate is then 14.6%, which is lower than 15%,
the commonly used baseline for determining whether
investments take place.
These concerns are supported by the little empirical
evidence that is available from the EU. In the period 2003 –
2008 a total of 25 genetically modified foods were approved.
Nineteen novel foods were approved and some 30 new
additives. It seems that less than one hundred product
16 Commission Recommendation 97/618/EC concerning the scientific aspects and the presentation of information necessary to support applications for the
placing on the market of novel foods and novel food ingredients and the preparation of initial assessment reports under Reg. 258/97, OJ 1997, L 253/1.
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innovations in the food sector requiring prior authorization
have actually been approved under EU prior authorization
schemes. This small quantity is in striking contrast to the
total number of innovations. Data for the entire food sector
are not available, but for the dairy sector alone Poppe et al.
identified over 1,400 innovations in the same period (Poppe
et al. 2009).
Also in the world of exotic foods – these are foods that
have a history outside the EU, but, due to a lack of history of
use inside the EU, are considered novel – the potential is
huge but hardly used. Worldwide, some 7,000 plants are
known to be used in the human food supply. About 300 of
these are likely to be considered traditional in the EU. Most
of the rest would come within the ambit of prior
authorization requirements if anyone tried to bring them to
the EU market (Knudsen et al. 2008). Thus, with the
potential of over 6,000 already existing food sources, only
five or six exotic plants or oils derived from such plants have
been approved for the EU market under the Novel Foods
Regulation.
WTO
From the above follows that, with regard to innovations in
food and agriculture, regulatory authorities face the challenge
to strike a fair balance between the requirements of safety –
that is consumer protection – and the interests of the business
sector. The considerable burden that pre-market approvals
place on businesses must be scientifically justified and not
constitute disguised restrictions on international trade.
According to the WTO SPS Agreement, members have
the right to adopt sanitary or phytosanitary measures
necessary for the protection of human, animal or plant life or
health, provided that such measures are based on scientific
principles and not maintained without sufficient scientific
evidence (Article 2 SPS). This requirement is further
elaborated in Article 5 SPS, which also provides for one
exception: Article 5.7 SPS allows to adopt provisional SPS
measures in cases where the scientific evidence is not
sufficient.17
Hence, although the choice of an appropriate level of
protection is perceived as a democratic choice of each WTO
member, food safety measures must meet rather strict risk
assessment requirements to be considered justified barriers
to trade.
Pre-market approval schemes are not forbidden under
WTO law, provided that certain conditions are met. Article 8
permits procedures aimed at ‘checking and ensuring the
fulfilment of SPS measures’ and undertaken in the context of
‘control, inspection, or approval’.18 Annex C sets out
requirements for these procedures. They have to be, i.a.,
undertaken and completed without undue delay and in no
less favourable manner for imported than for like domestic
products, the applicant has to be duly informed by the
competent authorities about the progress of the application at
all stages at the procedure, and any requirements for control,
inspection and approval of individual specimens of a product
must be limited to what is reasonable and necessary.
Concerning the Novel Foods Regulation, the Panel stated
in the Biotech Products case that the granting of marketing
approval for these foods is conditional, i.a., on a satisfactory
demonstration that the product for which approval is sought
not present a danger for the consumer. To the extent the Novel
Foods Regulation is applied for this purpose, it meets the
purpose element of the definition of an ‘SPS measure’.19 In
consequence, the pre-market approval procedure for novel
foods constitutes a procedure ‘to check and ensure the
fulfilment of SPS measures’within the meaning ofAnnex C.20
Thus, in the SPS Agreement pre-market authorizations
fall within the category of procedures aimed at checking and
ensuring the fulfilment of SPS measures. The risk analysis
paradigm is applied to individual authorization decisions
taken within the framework of the Novel Foods Regulation.21
However, the main issue that begs the question here is
whether the regulatory framework setting out the pre-market
approval requirement itself should be based on scientific
evidence.
Concerns over the legality of the Novel Foods Regulation
in the WTO forum were first raised in 2006 by a few
developing countries, including Peru, Ecuador and
Colombia, supported by interventions from other South
American and African countries. Peru in its communication
highlighted that, as a consequence of the implementation of
the regulation, exports of dehydrated lucuma meal (‘harina
de Lúcuma’) and yacon had been stopped.22 According to
Peru, the Novel Foods Regulation is therefore an
unnecessary and unjustified barrier to international trade
because of the very high costs of producing the scientific
studies required and a lengthy authorization procedure.23
As already mentioned, the main problem of the Novel
Foods Regulation is that it makes no distinction between
Regulatory challenges of innovation in food and agriculture
17 See also WTO Appellate Body Report, Japan – Measures Affecting Agricultural Products, WT/DS76/AB/R, adopted 19 Mar 1999 (Japan – Agricultural
Products II) for conditions that have to be met if Art. 5.7 SPS is to be applied.
18 WTO Reports of the Panels, European Communities – Measures Affecting the Approval and Marketing of Biotech Products, WT/DS291/R; WT/DS292/R;
WT/DS293/R, adopted 29 Sept. 2006, at para. 7.424.
19 Ibid., at para. 7.427.
20 Ibid., at para. 7.1491.
21 Ibid., at paras 1525-1526.
22 G/SPS/GEN/681 (5 Apr. 2006).
23 G/SPS/GEN/713 (12 July 2006). The trade concerns regarding Reg. 258/97 were raised again in 2011, after the EU institutions failed to agree on the revision
of the regulation, which aimed, i.a., at making the procedure for exotic novel foods simpler. See G/SPS/GEN/1087 (7 June 2011).
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strictly novel foods, i.e. those that have not been consumed
anywhere in the world, and those that are novel only in the
EU, e.g. exotic traditional products with a history of safe use
outside the EU. Such products are submitted to pre-market
authorization procedure in which the applicant has to prove
that a product is safe to consumers. These safety
considerations refer to a category of products determined
solely on the basis of an arbitrary date (May 1997), despite
the fact that some of them have been used safely for human
consumption for centuries in the country of origin and
elsewhere in the world.
Discussion and conclusion
The figures show that a side effect of the authorization
requirements is that comparatively few truly innovative foods
and crops become available for businesses and consumers. If
regulatory authorities want optimally to protect consumers
without unduly hampering innovation, they should apply
authorization schemes in the least intrusive way possible to
mitigate heavy burdens placed on industry.
The safety approach via prior authorization schemes
seems to be truly global. The schemes themselves, however,
remain national or regional. This means that the same
product has to be submitted to multiple risk analysis
procedures for the same purpose to acquire access to
different markets. Obviously, burdens both on authorities and
on businesses would be much reduced if authorities could
trust each other’s judgement on the safety of products to the
extent that they dare rely on them. To the extent risk
management authorities can recognise risk assessments
performed by (certain) foreign risk assessment bodies, one
single risk assessment procedure would provide a key to
many markets.
International trade law and international food standards
do not provide much guidance on pre-market approvals.
Most food safety pre-market approvals do, however, fall
under the SPS Agreement, which means that they have to be
scientifically justified. Legislatures are thus given a strong
incentive to exercise self-restraint in setting up prior
authorization schemes. These schemes should only be
required when scientific evidence shows that a risk to human,
animal or plant life or health exists.
Positive lists instead of individual authorizations should
be applied where possible. Similarly, flexible authorization
schemes, i.e. generic in principle, granting a specific
authorization only in justified cases, would help avoid
duplicating work.
Furthermore, pre-market approval schemes should
contain mechanisms to keep them up to date with the current
progress of science, by providing the option to exclude
certain categories of foods which can be ‘generally
recognized as safe’ in light of new scientific evidence.
Technologies that were ‘new’ in 1997 do not necessarily need
to raise safety concerns 15 years later. Updating the
regulation can also be done through issuing guidance
documents explaining which categories of foods fall within
the scope of broad legal definitions.
Finally, setting clear deadlines for authorities to complete
authorizations procedure is a minimum requirement (still
lacking in, e.g., the Novel Foods Regulation) that could
greatly increase the efficiency and predictability of the
system and decrease the costs of placing new products on the
market.
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